Unia Europejska - szwedzki - EMA (European Medicines Agency)

novartis europharm ltd. - aliskiren, amlodipin, hydroklortiazid - hypertension - kardiovaskulära systemet - rasitrio är indicerat för behandling av essentiell hypertoni som substitutionsbehandling hos vuxna patienter vars blodtryck är tillräckligt kontrollerat på kombinationen av aliskiren, amlodipin och hydroklortiazid ges samtidigt i samma dosnivå som i kombinationen.

Unia Europejska - szwedzki - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Unia Europejska - szwedzki - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, typ 2 - läkemedel som används vid diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. - , trippel kombinationsterapi) som ett komplement till kost och motion hos patienter bristfälligt kontrollerad på deras maximal tolererad dos av metformin och en sulphonylurea. sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Szwecja - szwedzki - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - metforminhydroklorid; sitagliptin - filmdragerad tablett - 50 mg/850 mg - sitagliptin 50 mg aktiv substans; metforminhydroklorid 850 mg aktiv substans; mannitol hjälpämne; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne

Szwecja - szwedzki - Läkemedelsverket (Medical Products Agency)

krka d.d., novo mesto - metforminhydroklorid; sitagliptin - filmdragerad tablett - 50 mg/1000 mg - sitagliptin 50 mg aktiv substans; mannitol hjälpämne; natriumlaurilsulfat hjälpämne; propylenglykol hjälpämne; metforminhydroklorid 1000 mg aktiv substans

Szwecja - szwedzki - Läkemedelsverket (Medical Products Agency)

sandoz a/s - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/1000 mg - natriumlaurilsulfat hjälpämne; sitagliptinhydrokloridmonohydrat 56,685 mg aktiv substans; metforminhydroklorid 1000 mg aktiv substans

Szwecja - szwedzki - Läkemedelsverket (Medical Products Agency)

sandoz a/s - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/850 mg - metforminhydroklorid 850 mg aktiv substans; sitagliptinhydrokloridmonohydrat 56,685 mg aktiv substans; natriumlaurilsulfat hjälpämne

Szwecja - szwedzki - Läkemedelsverket (Medical Products Agency)

orion corporation - metforminhydroklorid; sitagliptinhydrokloridmonohydrat - filmdragerad tablett - 50 mg/1000 mg - sitagliptinhydrokloridmonohydrat 56,69 mg aktiv substans; metforminhydroklorid 1000 mg aktiv substans; natriumlaurilsulfat hjälpämne